1. Home
  2. AXL vs CTMX Comparison

AXL vs CTMX Comparison

Compare AXL & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Axle & Manufacturing Holdings Inc.

AXL

American Axle & Manufacturing Holdings Inc.

HOLD

Current Price

$6.34

Market Cap

715.5M

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$4.08

Market Cap

596.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AXL
CTMX
Founded
1994
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
715.5M
596.2M
IPO Year
1999
2015

Fundamental Metrics

Financial Performance
Metric
AXL
CTMX
Price
$6.34
$4.08
Analyst Decision
Buy
Strong Buy
Analyst Count
7
6
Target Price
$6.93
$6.50
AVG Volume (30 Days)
2.9M
3.1M
Earning Date
11-07-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
46.55
50.22
EPS
0.34
0.24
Revenue
$5,833,600,000.00
$113,631,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$18.67
$17.07
Revenue Growth
N/A
N/A
52 Week Low
$3.00
$0.40
52 Week High
$7.03
$4.62

Technical Indicators

Market Signals
Indicator
AXL
CTMX
Relative Strength Index (RSI) 51.70 55.42
Support Level $6.40 $3.66
Resistance Level $6.65 $4.33
Average True Range (ATR) 0.25 0.28
MACD 0.02 -0.02
Stochastic Oscillator 62.94 72.38

Price Performance

Historical Comparison
AXL
CTMX

About AXL American Axle & Manufacturing Holdings Inc.

American Axle & Mfg Holdings Inc is engaged in manufacturing, engineering, designing, and validation of driveline systems and related components and chassis modules for light trucks, SUVs, crossover vehicles, passenger cars, and commercial vehicles. The company's segment includes Driveline and Metal Forming. It generates maximum revenue from the Driveline segment.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: